会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Hematopoietic stimulation
    • 造血刺激
    • US06770628B2
    • 2004-08-03
    • US09878792
    • 2001-06-11
    • Barbara P. WallnerBarry JonesGlenn T. MillerSharlene Adams
    • Barbara P. WallnerBarry JonesGlenn T. MillerSharlene Adams
    • A61K3804
    • A61K31/69A61K35/12A61K38/05A61K38/55A61K45/06
    • Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I: wherein m is an integer between 0 and 10, inclusive; A and A1 are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A1 and C, and between A1 and N are peptide bonds; and each X1 and X2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. A particularly preferred agent that is useful in practicing the invention is a ValBoroPro.
    • 提供了刺激造血作用的方法和产品,防止造血细胞水平降低并造成造血和成熟血细胞数量增加。 方法和产品可以在体内和体外使用。 所述方法包括施用式I的试剂:其中m为0至10的整数,包括端值; A和A1是L-氨基酸残基,使得每个重复括号中的A可以相同或不同的氨基酸残基; 与B结合的C处于L构型; A和N,A1和C之间以及A1和N之间的键是肽键; 并且每个X1和X2独立地是在生理pH下能够在水溶液中水解成羟基的羟基或基团。 可用于实施本发明的特别优选的试剂是ValBoroPro。
    • 5. 发明授权
    • Hematopoietic stimulation
    • 造血刺激
    • US06300314B1
    • 2001-10-09
    • US09304199
    • 1999-05-03
    • Barbara P. WallnerBarry JonesGlenn T. MillerSharlene Adams
    • Barbara P. WallnerBarry JonesGlenn T. MillerSharlene Adams
    • A61K3804
    • A61K31/69A61K35/12A61K38/05A61K38/55A61K45/06
    • Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I: wherein m is an integer between 0 and 10, inclusive; A and A1 are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A1 and C, and between A1 and N are peptide bonds; and each X1 and X2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. A particularly preferred agent that is useful in practicing the invention is a ValBoroPro.
    • 提供了刺激造血作用的方法和产品,防止造血细胞水平降低并造成造血和成熟血细胞数量增加。 方法和产品可以在体内和体外使用。 所述方法包括施用式I的试剂:其中m为0至10的整数,包括端值; A和A1是L-氨基酸残基,使得每个重复括号中的A可以相同或不同的氨基酸残基; 与B结合的C处于L构型; A和N,A1和C之间以及A1和N之间的键是肽键; 并且每个X1和X2独立地是在生理pH下能够在水溶液中水解成羟基的羟基或基团。 可用于实施本发明的特别优选的试剂是ValBoroPro。
    • 10. 发明申请
    • Purification of 1,1,1,3,3,3-Hexafluoroiopropanol
    • 1,1,1,3,3,3-六氟丙丙醇的纯化
    • US20080058560A1
    • 2008-03-06
    • US10599472
    • 2005-02-04
    • Paul MassellJoel SwinsonBarry JonesDaniel Graham
    • Paul MassellJoel SwinsonBarry JonesDaniel Graham
    • C07C29/132C07C29/74
    • C07C29/145C07C29/76C07C29/80C07C31/38
    • 1,1,1,3,3,3-Hexafluoroisopropanol (HFIP) substantially free of 1,1,1-trifluoroacetone (TFA) can be separated from a mixture containing both compounds by A) catalytic reduction with hydrogen followed by fractional distillation; B) cooling to a temperature at which HFIP freezes and TFA remains liquid; C) forming a high boiling complex comprising HF and TFA followed by fractional distillation; or D) producing HF-free conditions to yield a HFIP/TFA azeotrope followed by fractional distillation. It is emphasized that this abstract is provided to comply with the rules requiring an abstract, which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 CFR § 1.72(b).
    • 基本上不含1,1,1-三氟丙酮(TFA)的1,1,1,3,3,3-六氟异丙醇(HFIP)可以从含有这两种化合物的混合物中分离出来,A)用氢气催化还原,然后分馏; B)冷却至HFIP冻结的温度,TFA保持液态; C)形成包含HF和TFA的高沸点络合物,然后分馏; 或D)产生无HF条件以产生HFIP / TFA共沸物,随后进行分馏。 要强调的是,该摘要被提供以符合要求摘要的规则,这将允许搜索者或其他读者快速确定技术公开的主题。 提交它的理解是,它不会用于解释或限制权利要求的范围或含义。 37 CFR§1.72(b)。